新型口服抗流感药——奥司他韦

[1] Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. He G,Massarella J,Ward P. Clinical Pharmacokinetics . 1999

[2] Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Nicholson KG,Aoki FY,Osterhaus A,et al. The Lancet . 2000

[3] Costs and benefits of prevention and disease management. Musich SA,Burton WN,Edington DW. Disease Management and Health Outcomes . 1999

[4] Neuraminidase inhibitors: zanamivir and oseltamivir. McNicholl IR,McNicholl JJ. Annals of Pharmacotherapy . 2001

[5] Oseltamivir: a review of its use in influenza. McClellan K,Perry CM. Drugs . 2001

[6] Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. Colman PM,Hoyne PA,Lawrence MC. Journal of Virology . 1993

[7] Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza, randomized controlled trials for prevention and treatment. Hayden FG,Treanor JJ,Fritz RS,et al. The Journal of The American Medical Association . 1999

[8] Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza, a randomized controlled trial. Treanor JJ,Hayden FG,Vrooman PS,et al. The Journal of The American Medical Association . 2000

[9] Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. Hayden FG,Atmar RL,Schilling M,et al. The New England Journal of Medicine . 1999

[10] Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Kim CU,Lew W,Williams MA,et al. Journal of the American Chemical Society . 1997

[1] Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. He G,Massarella J,Ward P. Clinical Pharmacokinetics . 1999

[2] Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Nicholson KG,Aoki FY,Osterhaus A,et al. The Lancet . 2000

[3] Costs and benefits of prevention and disease management. Musich SA,Burton WN,Edington DW. Disease Management and Health Outcomes . 1999

[4] Neuraminidase inhibitors: zanamivir and oseltamivir. McNicholl IR,McNicholl JJ. Annals of Pharmacotherapy . 2001

[5] Oseltamivir: a review of its use in influenza. McClellan K,Perry CM. Drugs . 2001

[6] Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. Colman PM,Hoyne PA,Lawrence MC. Journal of Virology . 1993

[7] Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza, randomized controlled trials for prevention and treatment. Hayden FG,Treanor JJ,Fritz RS,et al. The Journal of The American Medical Association . 1999

[8] Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza, a randomized controlled trial. Treanor JJ,Hayden FG,Vrooman PS,et al. The Journal of The American Medical Association . 2000

[9] Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. Hayden FG,Atmar RL,Schilling M,et al. The New England Journal of Medicine . 1999

[10] Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Kim CU,Lew W,Williams MA,et al. Journal of the American Chemical Society . 1997